Table 1. Clinical characteristics of the study population, and frequency of the TP53 Arg72Pro genotypes in the indicated subpopulations.
| Total | Arg/Arg | Arg/Pro | Pro/Pro | ||
| All subjects | 487 | 250 (51.3%) | 210 (43.1%) | 27 (5.5%) | |
| Patients | 267 | 125 (46.8%) | 123 (46.1%) | 19 (7.1%) | |
| Controls | 220 | 125 (56.8%) | 87 (39.5%) | 8 (3.6%) | |
| Patient subgroups | |||||
| Mean age | 58.7±14.3 | 58.2±15.0 | 58.5±13.0 | 63.2±18.0 | |
| Median age | 60.2 | 60.2 | 58.8 | 67.6 | |
| Menopausal | pre | 61 | 30 (49.2%) | 25 (41.0%) | 6 (9.8%) |
| status | post | 172 | 78 (45.3%) | 83 (48.3%) | 11 (6.4%) |
| na | 34 | 17 (50.0%) | 15 (44.1%) | 2 (5.9%) | |
| Tumor size | pT1 | 132 | 64 (48.5%) | 57 (43.2%) | 11 (8.3%) |
| pT2 | 56 | 19 (33.9%) | 33 (58.9%) | 4 (7.1%) | |
| pT3, pT4 | 11 | 6 (54.5%) | 4 (36.4%) | 1 (9.1%) | |
| other, na | 68 | 36 (52.9%) | 29 (42.6%) | 3 (4.4%) | |
| Tumor type | ductal | 148 | 74 (50.0%) | 65 (43.9%) | 9 (6.1%) |
| lobular | 47 | 18 (38.3%) | 24 (51.1%) | 5 (10.6%) | |
| other, na | 72 | 33 (45.8%) | 34 (47.2%) | 5 (6.9%) | |
| Stage | 0, I | 112 | 54 (48.2%) | 49 (43.8%) | 9 (8.0%) |
| II | 63 | 25 (39.7%) | 35 (55.6%) | 3 (4.8%) | |
| III, IV | 20 | 11 (55.0%) | 7 (35.0%) | 2 (10.0%) | |
| na | 72 | 35 (48.6%) | 32 (44.4%) | 5 (6.9%) | |
| Grade | pG1 | 43 | 19 (44.2%) | 23 (53.5%) | 1 (2.3%) |
| pG2 | 114 | 47 (41.2%) | 55 (48.2%) | 12 (10.5%) | |
| pG3 | 88 | 49 (55.7%) | 34 (38.6%) | 5 (5.7%) | |
| na | 22 | 10 (45.5%) | 11 (50.0%) | 1 (4.5%) | |
| Nodal status | pN0 | 143 | 68 (47.6%) | 65 (45.5%) | 10 (7.0%) |
| pN+ | 53 | 23 (43.4%) | 27 (50.9%) | 3 (5.7%) | |
| na | 71 | 34 (47.9%) | 31 (43.7%) | 6 (8.5%) | |
| p53 status | pos | 56 | 29 (51.8%) | 24 (42.9%) | 3 (5.4%) |
| neg | 191 | 85 (44.5%) | 91 (47.6%) | 15 (7.9%) | |
| na | 20 | 11 (55.0%) | 8 (40.0%) | 1 (5.0%) | |
| ER status | pos | 196 | 86 (43.9%) | 95 (48.5%) | 15 (7.7%) |
| neg | 58 | 30 (51.7%) | 24 (41.4%) | 4 (6.9%) | |
| na | 13 | 9 (69.2%) | 4 (30.8%) | 0 (0.0%) | |
| PR status | pos | 137 | 56 (40.9%) | 70 (51.1%) | 11 (8.0%) |
| neg | 117 | 60 (51.3%) | 49 (41.9%) | 8 (6.8%) | |
| na | 13 | 9 (69.2%) | 4 (30.8%) | 0 (0.0%) | |
| HER2 status | pos | 51 | 30 (58.8%) | 16 (31.4%) | 5 (9.8%) |
| neg | 200 | 85 (42.5%) | 101 (50.5%) | 14 (7.0%) | |
| na | 16 | 10 (62.5%) | 6 (37.5%) | 0 (0.0%) | |
Numbers of patients in each of the indicated subgroups are shown. Numbers in parentheses indicate the fraction of patients (%) in each row with genotypes Arg/Arg, Arg/Pro and Pro/Pro, respectively. na, status not available; ER, estrogen receptor; PR, progesterone receptor. p53 IHC positivity indicates a TP53 mutation [53]. All p-values of subgroup comparisons were >0.05 (Chi2 tests).